Initial results from an in-progress Roswell Park Comprehensive Cancer Center clinical trial offer important insights into hormone receptor-positive and HER2-negative (HR+/HER2−) metastatic breast cancer and patient response to CDK4/6 inhibitors. This study, newly published in NPJ Precision Oncology, identifies pathological and biological features associated with therapeutic response in these patients — suggesting possible treatment strategies for this common breast cancer subtype.

Eighteen months ago, Roswell Park Comprehensive Cancer Center announced a plan to build a new freestanding location in Amherst, N.Y., that would extend convenient access to outstanding cancer care and services for patients in Buffalo’s northern suburbs. Today, the cancer center welcomed patients, cancer survivors and community members into that center — Roswell Park Scott Bieler Amherst Center — for the first time at a grand-opening event.